Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

2646 - Impact of BRCA status on outcomes and survival in high-risk early breast cancers

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Elodie Klajer

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

E. Klajer1, S. Paget-Bailly2, G. Meynard1, A. Meurisse2, F. Bazan1, L. Chaigneau1, E. Dobi1, N. Meneveau1, P. Montcuquet1, C. Villanueva1, A. Thiery-Vuillemin1, E. Kalbacher1, C. Populaire3, M. Collonge-Rame3, J. Gligorov4, E. Curtit1, X. Pivot5, L. Mansi1

Author affiliations

  • 1 Medical Oncology, CHU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR
  • 2 Methodology And Quality Of Life In Oncology Unit, Umr 1098, CHU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR
  • 3 Medical Biologic Genetic And Clinical Oncogenetic, CHU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR
  • 4 Medical Oncology Dept, APHP, CancerEst, Tenon University Hospital, 75020 - Paris/FR
  • 5 Medical Oncology, Centre Paul Strauss Centre de Lutte contre le Cancer, 67065 - Strasbourg/FR
More

Resources

Abstract 2646

Background

Relationship between the presence of the BRCA mutation (BReast CAncer) and outcomes is unclear, especially in high-risk breast cancers. The aims were to describe clinical and pathological outcomes considering mutational status and to assess the prognostic impact of germinal BRCA mutated status (BRCAm) in this high-risk population.

Methods

A multi-center retrospective cohort of patients treated in Franche-Comté between 2003 and 2013 for an early breast cancer (eBC) by neoadjuvant and/or adjuvant chemotherapy was analyzed. Clinical and pathological outcomes were described and distributions were compared in regards of mutational status group performing Fisher exact tests. Kaplan-Meier method and log-rank tests were used to compare survival in terms of overall survival (OS. Univariate and multivariate Cox proportional hazards models were estimated for OS.

Results

A total of 2,295 patients were included. Among them, 240 patients were tested (10.5%) including 60 patients diagnosed with BRCAm (2.6%). Among them, 36 were BRCA1 (1.6%), 22 BRCA2 (1%) and two BRCA1 and 2 (0.01%). Age at diagnosis (p < 0.0001), histological type (p = 0.0043), size (p = 0.0021), nodal status (p < 0.0001), histologic grade (p = 0.0009), triple negative status (p < 0.0001) and in situ component (p = 0.0163) were significantly different between BRCAm, BRCAwt and untested patients. BRCA1 mutated tumors were mostly triple negative tumors contrary to BRCA2 mutated tumors, which were mostly locally advanced luminal tumors. In multivariate analysis, OS was not associated with BRCAm status (p = 0.5690).

Conclusions

Among this French cohort of high-risk eBC, incidence of BRACm cases was 2.6%. BRCA1 and BRCA2 breast cancers were two distinct tumors in term of pathological outcomes. BRCAm status had no significant impact on OS.

Clinical trial identification

Legal entity responsible for the study

CHU Besançon.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings